Cargando…
Humoral immunity against SARS‐CoV‐2 variants including omicron in solid organ transplant recipients after three doses of a COVID‐19 mRNA vaccine
OBJECTIVES: Solid organ transplant recipients (SOTR) receiving post‐transplant immunosuppression show increased COVID‐19‐related mortality. It is unclear whether an additional dose of COVID‐19 vaccines can overcome the reduced immune responsiveness against severe acute respiratory syndrome coronavir...
Autores principales: | Saharia, Kapil K, Husson, Jennifer S, Niederhaus, Silke V, Iraguha, Thierry, Avila, Stephanie V, Yoo, Youngchae J, Hardy, Nancy M, Fan, Xiaoxuan, Omili, Destiny, Crane, Alice, Carrier, Amber, Xie, Wen Y, Vander Mause, Erica, Hankey, Kim, Bauman, Sherri, Lesho, Patricia, Mannuel, Heather D, Ahuja, Ashish, Mathew, Minu, Avruch, James, Baddley, John, Goloubeva, Olga, Shetty, Kirti, Dahiya, Saurabh, Rapoport, Aaron P, Luetkens, Tim, Atanackovic, Djordje |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9052011/ https://www.ncbi.nlm.nih.gov/pubmed/35505864 http://dx.doi.org/10.1002/cti2.1391 |
Ejemplares similares
-
Vaccine-induced T-cell responses against SARS-CoV-2 and its Omicron variant in patients with B cell–depleted lymphoma after CART therapy
por: Atanackovic, Djordje, et al.
Publicado: (2022) -
T cell responses against SARS-CoV-2 and its Omicron variant in a patient with B cell lymphoma after multiple doses of a COVID-19 mRNA vaccine
por: Atanackovic, Djordje, et al.
Publicado: (2022) -
Chimeric antigen receptor (CAR) T cells for the treatment of a kidney transplant patient with post-transplant lymphoproliferative disorder (PTLD)
por: Kline, Kathryn, et al.
Publicado: (2023) -
Anti-SARS-CoV-2 Immune Responses in Patients Receiving an Allogeneic Stem Cell or Organ Transplant
por: Atanackovic, Djordje, et al.
Publicado: (2021) -
Impaired immune response to COVID-19 vaccination in patients with B-cell malignancies after CD19 CAR T-cell therapy
por: Dahiya, Saurabh, et al.
Publicado: (2022)